08:20 AM EST, 01/06/2025 (MT Newswires) -- Algernon Pharmaceuticals ( AGNPF ) on Monday said it received a notice of allowance from the United States Patent and Trademark Office for Repirinast, the company's lead chronic kidney disease (CKD) drug.

The company has corresponding patents in Japan and China and has applications pending in Europe and Canada.

Repirinast is Algernon's lead candidate for the treatment of CKD, with data showing it reduced fibrosis by 51%.